Gemcitabine Epirubicin

Pei, J., Zhang, C., Gokhale, PC., Rahman, A., Dritschilo, A., Ahmad, I., and Kasid, U. (2004) Combination with liposome-entrapped, ends-modified raf anti-sense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cis-platin, epirubicin, mitoxantrone, docetaxel, and gemcitabine. Anticancer Drugs 15, 243-253. 

The concurrent use of gemcitabine and doxorubicin or epirubicin does not appear to affect the pharmacokinetics of either drug. An in vitro study found that the efficacy of the combination of gemcitabine and epirubicin may be schedule-dependent. 

The pharmacokinetics of gemcitabine and doxorubicin did not differ when they were given on the same day, when compared with when they were given alone in patients with breast cancer. Similarly, gemcitabine pharmacokinetics were unchanged by the concurrent use of epirubicin and paclitaxel in patients with breast cancer, and gemcitabine did not alter the interaction between epirubicin and paclitaxel (see Anthracyclines -i-Taxanes , p.612). 

An in vitro study using human bladder cancer cells found that both gemcitabine and epirubicin alone exerted a cytotoxic effect but the efficacy of the combination of epirubicin and gemcitabine depended on the schedule... 

---